The United States Food and Drug Administration (FDA) has authorized lisdexamfetamine dimesylate (Vyvanse, Shire) to treat binge eating condition (BED) in grownups. The drug is the first FDA-approved medication to treat this condition.
“Binge eating can cause major illness and problems with work, home, and social life,” stated Mitchell Mathis, MD, director of the Department of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research Study. “The approval of Vyvanse supplies doctors and patients with a reliable alternative to assist suppress episodes of binge consuming.”
Vyvanse was examined under the FDA’s top priority review program, which provides for a sped up review of drugs that are planned to deal with a serious illness or condition which might supply a significant improvement over readily available treatment.
The efficacy of Vyvanse in treating BED was displayed in 2 medical research studies that included 724 adults with moderate to extreme BED, as reported by Medscape Medical News. In the research studies, participants taking Vyvanse experienced a decrease in the number of binge eating days per week and had fewer obsessive-compulsive binge eating behaviors compared with patients in a placebo group.
The most typical consuming condition among grownups in the United States, BED affects an estimated 2.8 million United States grownups and is more common than anorexia and bulimia nervosa combined.
It was formally recognized as a distinct disorder in the brand-new Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, which was launched by the American Psychiatric Association in 2013.
Vyvanse is dispensed with a medication guide for patients, which offers essential details about the medication’s usage and risks. The most severe risks consist of psychiatric issues and heart issues, consisting of abrupt death in people who have heart issues or heart flaws, and stroke and cardiovascular disease in adults.
Central nerve system stimulants, such as Vyvanse, might trigger psychotic or manic symptoms, such as hallucinations, delusional thinking, or mania, even in people without a previous history of psychotic disease.
The most typical side effects reported by people taking Vyvanse in the clinical trials consisted of dry mouth, sleeplessness (sleeping disorders), increased heart rate, jittery sensations, irregularity, and anxiety.
Vyvanse is not approved for, or advised for, weight reduction. Its effectiveness for weight loss has not been studied, the FDA notes.
In 2007, the drug was authorized by the FDA as a once-daily medication to deal with attention-deficit/hyperactivity condition (ADHD) in clients aged 6 years and older. Vyvanse is a Schedule II illegal drug because it has high capacity for abuse, with use possibly resulting in dependence.
Vyvanse is marketed by Shire United States, Inc, based in Wayne, Pennsylvania.
The FDA revealed it has expanded making use of a drug approved for ADHD to deal with binge eating condition.
